A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Reynolds K.L.Bedard P.L.Lee S.-H.Chia-Chi LinTabernero J.Alsina M.Cohen E.Baselga J.Blumenschein G.Graham D.M.Garrido-Laguna I.Juric D.Sharma S.Salgia R.Seroutou A.Tian X.Fernandez R.Morozov A.Sheng Q.Ramkumar T.Zubel A.Bang Y.-J.2022-09-152022-09-1520171471-2407https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029370515&doi=10.1186%2fs12885-017-3641-6&partnerID=40&md5=7326ca42e21909502009ab2b3452803fhttps://scholars.lib.ntu.edu.tw/handle/123456789/620279[SDGs]SDG3A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerjournal article10.1186/s12885-017-3641-6288993632-s2.0-85029370515